These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9812567)

  • 1. [Clinical significance of determining serum soluble IL-6 receptor concentration in plasma cell dyscrasias].
    Hou J; Zhao Y; Liu Y
    Zhonghua Nei Ke Za Zhi; 1997; 36(2):94-6. PubMed ID: 9812567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma.
    Urbańska-Ryś H; Wiersbowska A; Stepień H; Robak T
    Eur Cytokine Netw; 2000 Sep; 11(3):443-51. PubMed ID: 11022130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating IL-6-type cytokines and sIL-6R in patients with multiple myeloma.
    Wierzbowska A; Urbańska-Ryś H; Robak T
    Br J Haematol; 1999 May; 105(2):412-9. PubMed ID: 10233412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity.
    Papadaki H; Kyriakou D; Foudoulakis A; Markidou F; Alexandrakis M; Eliopoulos GD
    Acta Haematol; 1997; 97(4):191-5. PubMed ID: 9158660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma.
    Stasi R; Brunetti M; Parma A; Di Giulio C; Terzoli E; Pagano A
    Cancer; 1998 May; 82(10):1860-6. PubMed ID: 9587117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of IL-6 and its soluble receptor (sIL-6R) in Waldenström's macroglobulinemia.
    Hatzimichael EC; Christou L; Bai M; Kolios G; Kefala L; Bourantas KL
    Eur J Haematol; 2001 Jan; 66(1):1-6. PubMed ID: 11168500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
    Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS
    Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum Levels of Interleukin-8 and Soluble Interleukin-6 Receptor in Patients with Stage-I Multiple Myeloma: A Case-Control Study.
    Kohsari M; Khadem-Ansari MH; Rasmi Y; Sayyadi H
    Asian Pac J Cancer Prev; 2020 Jan; 21(1):127-132. PubMed ID: 31983174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble IL-6R in plasma cell dyscrasias.
    Smith SR; Morgan L
    Leuk Lymphoma; 1997 Aug; 26(5-6):489-95. PubMed ID: 9389356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Study on serum soluble interleukin-6 receptor levels in patients with malignant hematological diseases].
    Li D; Yang J; Cui W; Ma C; Ma C; Ji E; Li J; Li G; Ma C
    Zhonghua Xue Ye Xue Za Zhi; 1997 Nov; 18(11):577-80. PubMed ID: 15625895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy.
    Gaillard JP; Bataille R; Brailly H; Zuber C; Yasukawa K; Attal M; Maruo N; Taga T; Kishimoto T; Klein B
    Eur J Immunol; 1993 Apr; 23(4):820-4. PubMed ID: 8458373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of elevated soluble interleukin-6 receptor levels in the sera of patients with plasma cell dyscrasias.
    Ohtani K; Ninomiya H; Hasegawa Y; Kobayashi T; Kojima H; Nagasawa T; Abe T
    Br J Haematol; 1995 Sep; 91(1):116-20. PubMed ID: 7577617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum interleukin-6 receptor in polymyalgia rheumatica: a potential marker of relapse/recurrence risk.
    Pulsatelli L; Boiardi L; Pignotti E; Dolzani P; Silvestri T; Macchioni P; Cantini F; Salvarani C; Facchini A; Meliconi R
    Arthritis Rheum; 2008 Aug; 59(8):1147-54. PubMed ID: 18668607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Soluble interleukin-6 receptors in the serum in multiple myeloma].
    Scudla V; Kubalová D; Bacovský J; Lukes J; Vavrdová V
    Cas Lek Cesk; 1996 Nov; 135(22):719-22. PubMed ID: 8998823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abnormal regulation of soluble and anchored IL-6 receptor in monocytes from patients with essential thrombocythemia.
    Goette NP; Lev PR; Heller PG; Glembotsky AC; Chazarreta CD; Salim JP; Molinas FC; Marta RF
    Exp Hematol; 2010 Oct; 38(10):868-876.e1. PubMed ID: 20600579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis.
    Robak T; Gladalska A; Stepień H; Robak E
    Mediators Inflamm; 1998; 7(5):347-53. PubMed ID: 9883970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relation of serum levels of the soluble cytoadhesion molecules sVCAM-1 and sICAM-1 to selected factors in the cytokine network in multiple myeloma].
    Scudla V; Budíková M; Bacovský J; Opíchalová D; Farbiaková V
    Cas Lek Cesk; 2000 Jul; 139(13):401-6. PubMed ID: 10971970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-6 and sIL-6R concentration in the cerebrospinal fluid and serum of MS patients.
    Stelmasiak Z; Kozioł-Montewka M; Dobosz B; Rejdak K
    Med Sci Monit; 2001; 7(5):914-8. PubMed ID: 11535934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum soluble IL-6 receptor concentrations correlate with stages of multiple myeloma defined by serum beta 2-microglobulin and C-reactive protein.
    Kyriakou D; Papadaki H; Eliopoulos AG; Foudoulakis A; Alexandrakis M; Eliopoulos GD
    Int J Hematol; 1997 Oct; 66(3):367-71. PubMed ID: 9401283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD8+CD28-lymphocytes in peripheral blood and serum concentrations of soluble interleukin 6 receptor are increased in patients with Graves' orbitopathy and correlate with disease activity.
    Slowik M; Urbaniak-Kujda D; Bohdanowicz-Pawlak A; Kapelko-Slowik K; Dybko J; Wolowiec D; Jazwiec B; Daroszewski J
    Endocr Res; 2012; 37(2):89-95. PubMed ID: 22489922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.